Arcadia Investment Management’s F-star Therapeutics, Inc. Common Stock FSTX Stock Holding History

Arcadia Investment Management’s Portfolio FSTX Stock Details FSTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-3,000	Closed	-$15K	–	296
2021 Q4	$15K	Hold	3,000	–	–	﹤0.01%	252
2021 Q3	$22K	Hold	3,000	–	–	﹤0.01%	231
2021 Q2	$26K	Hold	3,000	–	–	﹤0.01%	228
2021 Q1	$32K	Hold	3,000	–	–	0.01%	221
2020 Q4	$30K	Hold	3,000	–	–	0.01%	210
2020 Q3	$16K	Hold	3,000	–	–	﹤0.01%	246
2020 Q2	$18K	Hold	3,000	–	–	﹤0.01%	239
2020 Q1	$11K	Hold	3,000	–	–	﹤0.01%	264
2019 Q4	$19K	Hold	3,000	–	–	﹤0.01%	249
2019 Q3	$41K	Hold	3,000	–	–	0.01%	208
2019 Q2	$44K	Buy	+3,000	New	+$80.4K	0.01%	210

Other funds holding FSTX

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AVA

Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Arcadia Investment Management's FSTX Position: Q1 2022 in Review

Arcadia Investment Management sold out of F-star Therapeutics, Inc. Common Stock (FSTX) in Q1 2022, closing a stake of 3,000 shares — an estimated $15K sold.

Arcadia Investment Management first reported a position in FSTX in Q2 2019 and held it in 11 quarters. The position peaked at $44K in Q2 2019. 40 funds tracked by Wall St. Rank hold FSTX as of Q1 2022.

Arcadia Investment Management reported no remaining F-star Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
Arcadia Investment Management sold 3,000 F-star Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $15K.
Arcadia Investment Management first reported a position in F-star Therapeutics, Inc. Common Stock in Q2 2019 and held it in 11 quarters.
Arcadia Investment Management's F-star Therapeutics, Inc. Common Stock position peaked at $44K in Q2 2019.
40 funds tracked by Wall St. Rank held F-star Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Arcadia Investment Management's 13F filing for Q1 2022, filed 28 Apr 2022.